ArticleAllergy2025
Clinical, Epidemiological, Virological Characteristics and Outcomes of 286 Patients Infected With Monkeypox Virus in China.
Article in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of human immunodeficiency virus coinfection on mpox patients during the 2022 global outbreak: a systematic review and meta-analysis based on comparative observational studies.Frontiers in microbiology · 2026Pooled it
- A HIV status-stratified analysis of Mpox risk factors among MSM in Mainland China over two years (2023-2024).BMC public health · 2026Article
- Clinical and radiological features of severe mpox: a case series of 16 patients in Beijing, China.BMC infectious diseases · 2026Article
- Ocular manifestations of Clade Ib mpox in four South-Kivu health zones, Democratic Republic of the Congo.PLOS global public health · 2026Article
- Clinical, epidemiological, and genomic evidence on mpox in mainland China, 2022-2025: a scoping review.Frontiers in microbiology · 2026Review
- Review
- Disparity in Mpox awareness and vaccine hesitancy: a cross-sectional study of 3,483 university students in Northwest China.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundMonkeypox virus (mpox) outbreak since 2022 has already constituted a public health emergency of international concern. A comprehensive study on epidemiological features, symptoms and signs, complications, sequelae, and clinical outcomes has been lacking. Accordingly, we performed a large-scale multicenter study to comprehensively summarize the clinical, epidemiological, behavioral, laboratory, virological characteristics, and treatment-related outcomes of mpox in China.
methodIn this multicenter hospital-based retrospective study, demographic information, clinical characteristics, laboratory results, hospitalization records, prescribed medications, and clinical outcomes were extracted from the electronic medical records of 286 confirmed mpox cases from five regions of China.
resultAn approximately 1:1 ratio of HIV-positive (52.1%) and HIV-negative was found, with an overall median age of 32 years (IQR 27-37). Most patients were male (99.3%), lived in urban areas (86.0%), single (72.6%), and had a college degree or higher (62.0%). Men having sex with men (MSM) was the predominant sexual orientation (83.0%), and sexual contact was the most likely mode of exposure (85.4%). 17 (9.6%) patients reported a history of smallpox vaccination. Hundered and seven patients had at least one co-morbid other sexually transmitted infection. Fourteen patients had a self-reported history of allergy. Significant differences were found between HIV-negative and HIV-positive mpox in the proportion of MSM, anal and perianal pain, levels of AST, CRP, CD4+ T-cell, CD8+ T-cell, NK-cell levels, and clinical outcomes.
conclusionMSM individuals with an interquartile age range of 27-37 years, particularly from coastal or developed regions of China, were identified as "main affected population" for mpox prevention and control. HIV infection may contribute to more severe mpox manifestations, characterized by elevated AST and CRP levels, reduced CD4 + T-cell and NK-cell counts, and unfavorable clinical outcomes with increased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.